cme information
Accreditation & Credit Designation Statements
Physicians
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). The International Association for the Study of Lung Cancer is accredited by the ACCME to provide continuing medical education for physicians.
The International Association for the Study of Lung Cancer designates the hybrid format for this educational activity for a maximum of 65.00 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
US Nurse Practitioners and Registered Nurses
For the purpose of recertification, the American Nurses Credentialing Center accepts AMA PRA Category 1 Credit™ issued by organizations accredited by the ACCME (Accreditation Council for Continuing Medical Education).
US Physician Assistants
The National Commission on Certification of Physician Assistants (NCCPA) states that the AMA PRA Category 1 Credits™ are acceptable for continuing medical education requirements for recertification.
How to Receive a CME Certificate/Certificate of Attendance
The claim credit process and conference evaluation will be available online starting September 15 through December 31, 2026, in the IASLC Lung Cancer 360.
- Log in using your Lung Cancer 360 Username and Password
- Select the sessions you attended
- Complete the conference evaluation
- Download your certificate.
If you are new to Lung Cancer 360 or forgot your password, click the Reset Password link. For assistance, please email [email protected].
At the conclusion of this activity, participants should be able to:
Advance Multidisciplinary Care in Thoracic Oncology:
Make use of evidence-based strategies across surgery, radiation oncology, medical oncology, pathology, radiology, pulmonology, nursing, and supportive care to optimize outcomes for patients with thoracic malignancies.
Evaluate Innovations in Screening, Early Detection, and Prevention:
Assess advances in lung cancer screening, risk prediction, biomarker-driven detection, imaging technologies, and prevention strategies to facilitate earlier diagnosis and reduce disease burden.
Implement Personalized Treatment Approaches:
Apply current evidence on molecular testing, biomarker-driven therapies, antibody-drug conjugates (ADCs), targeted therapies, immunotherapies, and emerging treatment modalities to tailor care across thoracic malignancies.
Explore the Evolving Landscape of Immunotherapy and Novel Therapeutics:
Critically evaluate emerging data on immune checkpoint inhibitors, novel immunotherapeutic approaches, combination strategies, mechanisms of resistance, and next-generation therapeutic platforms to improve patient outcomes.
Enhance Management Across the Spectrum of Thoracic Malignancies:
Discuss best practices and evolving approaches for early-stage, locally advanced, and advanced thoracic cancers, including small cell lung cancer, mesothelioma, thymic malignancies, and other rare thoracic tumors.
Integrate Emerging Diagnostic, Monitoring, and Digital Technologies:
Evaluate the utility of liquid biopsies, circulating tumor DNA (ctDNA), multiomic profiling, advanced imaging, artificial intelligence, and digital pathology for diagnosis, treatment selection, monitoring, and surveillance.
Improve Global Access, Equity, and Patient-Centered Care:
Identify barriers and implement strategies to improve access to screening, molecular testing, clinical trials, survivorship resources, and evidence-based treatment while incorporating patient preferences and quality-of-life considerations.
Foster Interactive Learning and Collaborative Problem-Solving:
Apply new knowledge to complex clinical scenarios and enhance decision-making in thoracic oncology through case-based discussions, audience engagement, multidisciplinary debate, and peer-to-peer learning.
The International Association for the Study of Lung Cancer (IASLC) complies with the Standards for Integrity and Independence in Accredited Continuing Education of the Accreditation Council for Continuing Medical Education (ACCME). IASLC applies these Standards throughout the educational planning process to ensure independence, balance, objectivity and scientific rigor for all Continuing Medical Education (CME) activities.
In compliance with the ACCME Standards, each individual in a position to control the content of a CME activity is required to disclose all financial relationships with ACCME defined ineligible companies. All disclosures are reviewed to identify relevant financial relationships and any conflicts of interest are mitigated before the individual can assume their role in the activity.
All disclosures will be made available no later than September 12, 2026.
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of the IASLC or any company that provided commercial support for this activity.
In accordance with the standards and guidance set forth by the Accreditation Council for Continuing Medical Education (ACCME), individuals in control of content are required to disclose the use of artificial intelligence (AI) in the development of educational materials. This includes identification of the specific AI tool(s) utilized and a description of how AI contributed to content creation.
IASLC maintains oversight of all educational content and conducts a thorough review process to ensure that materials are evidence-based, fair-balanced, and free from commercial bias, consistent with ACCME Standards for Integrity and Independence.
While AI may be used as a supportive tool in content development, it does not replace clinical expertise or independent medical judgment. Learners are advised to critically evaluate all information presented and apply their own professional judgment when incorporating knowledge into clinical practice.
The IASLC 2026 World Conference on Lung Cancer (WCLC 2026) is the world’s largest international conference dedicated to advancing the prevention, diagnosis, treatment, and management of lung cancer and other thoracic malignancies. Bringing together clinicians, researchers, scientists, nurses, allied health professionals, patient advocates, and other members of the multidisciplinary care team from around the world, the conference provides opportunities to evaluate emerging evidence, exchange scientific knowledge, and translate advances in research into clinical practice.
With 20 educational tracks and more than 300 invited experts, WCLC 2026 offers a comprehensive scientific program addressing the full spectrum of thoracic oncology, including tumor biology and biomarkers, screening and early detection, precision medicine, targeted therapies, immunotherapy, liquid biopsy, artificial intelligence and digital technologies, tobacco control, survivorship, health equity, and patient advocacy. Through plenary sessions, expert lectures, panel discussions, oral abstract presentations, posters, and interactive educational formats, participants will gain knowledge and practical strategies to improve multidisciplinary care, enhance patient outcomes, and advance equitable access to high-quality thoracic cancer care worldwide.
The IASLC 2026 World Conference on Lung Cancer is designed to meet the educational needs of researchers and healthcare professionals who diagnose and treat patients with lung cancer, including medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, radiologists, pathologists, advanced practice nurses, and physician assistants.
The below list includes countries that accept ACCME-accredited continuing medical education (CME). Please note that some countries that accept ACCME-accredited education do not have specific credit requirements for their physicians. For additional information: https://accme.org/about-accreditation/countries-accepting-accme-accredited-cme/
Antigua & Barbuda
REGULATOR
Antigua & Barbuda Medical Council
Austria
REGULATOR
Austrian Academy of Physicians on behalf of the Austrian Medical Chamber
Bahamas
REGULATOR
Bahamas Medical Council
Belgium
REGULATOR
Group of Belgian Professional Unions of Specialist Doctors
Bhutan
REGULATOR
Medical and Health Professional Council, Royal Government of Bhutan
Croatia
REGULATOR
Croatian Medical Chamber
Gambia, The
REGULATOR
The Medical and Dental Council of the Gambia
Germany
REGULATOR
State Chambers of Physicians in the 16 federal states
(only in-person, live events)
India, State of Punjab
REGULATOR
Punjab Medical Council
Israel
REGULATOR
Scientific Council, Israeli Medical Association
Jamaica
REGULATOR
Medical Council of Jamaica
Kuwait
REGULATOR
Professional Licensing - Ministry of Health
Malawi
REGULATOR
Medical Council of Malawi
Malaysia
REGULATOR
Malaysian Medical Council
Number of credits required
20 points/year
Netherlands, The
REGULATOR
Royal Dutch Society of the Promotion of Medicine
Oman
REGULATOR
Oman Medical Specialty Board
Qatar
REGULATOR
Accreditation Section of the Department of Healthcare Professions of the Qatar Ministry of Public Health
Rwanda
REGULATOR
Rwanda Medical & Dental Council
Saudi Arabia
REGULATOR
Saudi Commission for Health Specialties
Singapore
REGULATOR
Singapore Medical Council
South Africa
REGULATOR
Health Professions Council of South Africa
Spain
REGULATOR
Spanish Medical Professional Accreditation Council for CPD/CME
Sri Lanka
REGULATOR
Sri Lanka Medical Council, Sri Lanka Medical Association, and the Ministry of Health
Sweden
REGULATOR
Swedish Medical Association
Tunisia
REGULATOR
INEAS (Instance Nationale de l'Evaluation et de l'Accréditation en santé)
Trinidad & Tobago
REGULATOR
The Trinidad and Tobago Medical Association
Turkey
REGULATOR
Turkish Medical Association CME-CPD Accreditation Council
United Arab Emirates, Abu Dhabi
REGULATOR
Department of Health
United Arab Emirates, Dubai
REGULATOR
Dubai Health Authority
The official language of the IASLC 2026 World Conference on Lung Cancer is English.
Disclaimer
The information presented at WCLC 2026 is that of the contributing faculty and does not necessarily represent the views of the International Association for the Study of Lung Cancer and/or any named commercial entity providing financial support. Specific therapies discussed may not be approved and/or specified for use as indicated by the faculty presenters. Therefore, before prescribing any medication, please review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse effects.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.